Department of Dermatology, Université Nice Côte d'Azur, Centre Hospitalier Universitaire Nice, Nice, France.
INSERM U1065, C3M, team 12, Université Nice Côte d'Azur, Nice, France.
JAMA Dermatol. 2018 Dec 1;154(12):1453-1456. doi: 10.1001/jamadermatol.2018.2191.
Hailey-Hailey disease (HHD) is a rare, autosomal-dominant acantholytic dermatosis characterized clinically by development of recurrent blisters and erosions in friction areas. Despite progression in our understanding of the molecular genetics of HHD, therapy remains suboptimal and there is no known cure.
To determine whether the novel phosphodiesterase-4 inhibitor apremilast is effective in the treatment of HHD.
DESIGN, SETTING, AND PARTICIPANTS: Clinical case series of 4 patients with severe, treatment-resistant HHD at an outpatient clinic in the Department of Dermatology of Nice University Hospital, Nice, France. The patients were treated with apremilast; after the initial titration, the dose was 30 mg, twice daily.
Objective clinical response was assessed by the treating dermatologist using the physician global assessment score; recorded adverse effects were monitored throughout the treatment at intervals of 2 to 3 months.
Three women and 1 man, with a mean age of 56 years, were treated and followed up for 6 to 10 months. Family history of the disease was noted in 3 (75%) of the cases. The lesions affected the axillary regions (75%), submammary regions (75%), inguinal regions (100%), and back and neck areas (50%). An improvement in the symptoms was reported by all of the patients after a treatment period of 1 month. After 6 months, the improvement of HHD lesions was reported as moderate to almost cleared among the patients. However, 2 patients developed some flares after 6 to 10 months of treatment and stopped apremilast therapy. One of the patients developed uncontrolled diffuse lesions and apremilast was reintroduced, resulting in partial control of her disease.
Apremilast appears to offer a low-risk therapeutic alternative or adjunct in resistant and severe forms of HHD. A prospective controlled trial with long-term follow-up is required to confirm these preliminary observations.
Hailey-Hailey 病(HHD)是一种罕见的常染色体显性遗传性棘层松解性皮肤病,临床上表现为摩擦部位反复出现水疱和糜烂。尽管我们对 HHD 的分子遗传学有了进一步的了解,但治疗方法仍然不理想,也没有已知的治愈方法。
确定新型磷酸二酯酶 4 抑制剂阿普米司特治疗 HHD 的疗效。
设计、地点和参与者:法国尼斯大学医院皮肤科门诊的 4 例严重、治疗抵抗的 HHD 患者的临床病例系列。患者接受阿普米司特治疗;初始滴定后,剂量为 30mg,每日 2 次。
治疗医生使用医生总体评估评分评估客观临床反应;在整个治疗过程中,每 2 至 3 个月监测一次记录的不良反应。
3 名女性和 1 名男性,平均年龄 56 岁,接受治疗并随访 6 至 10 个月。3 例(75%)有疾病家族史。病变累及腋窝(75%)、乳房下区域(75%)、腹股沟区域(100%)和背部及颈部区域(50%)。所有患者在治疗 1 个月后均报告症状改善。6 个月后,患者报告 HHD 病变改善为中度至几乎清除。然而,2 例患者在治疗 6 至 10 个月后出现一些病情加重并停止使用阿普米司特治疗。其中 1 例患者出现无法控制的弥漫性病变,重新引入阿普米司特,使疾病得到部分控制。
阿普米司特似乎为耐药和严重形式的 HHD 提供了一种低风险的治疗选择或辅助治疗。需要进行长期随访的前瞻性对照试验来证实这些初步观察结果。